Sk Biopharmaceuticals Co Ltd (326030) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.095x

Based on the latest financial reports, Sk Biopharmaceuticals Co Ltd (326030) has a cash flow conversion efficiency ratio of 0.095x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩65.41 Billion ≈ $44.33 Million USD) by net assets (₩689.46 Billion ≈ $467.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Sk Biopharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Sk Biopharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Sk Biopharmaceuticals Co Ltd (326030) total liabilities for a breakdown of total debt and financial obligations.

Sk Biopharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sk Biopharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Tianfeng Securities Co Ltd SHG:601162	-0.104x
ServiceTitan, Inc. Class A Common Stock NASDAQ:TTAN	26.606x
Wallenius Wilhelmsen Logistics ASA OL:WAWI	0.135x
CarMax Inc NYSE:KMX	0.207x
H Lundbeck A/S CO:HLUN-B	0.014x
Jiangsu Hoperun Software Co Ltd SHE:300339	-0.007x
JA Solar Technology Co Ltd SHE:002459	0.010x
Etsy, Inc. NASDAQ:ETSY	-0.197x

Annual Cash Flow Conversion Efficiency for Sk Biopharmaceuticals Co Ltd (2016–2024)

The table below shows the annual cash flow conversion efficiency of Sk Biopharmaceuticals Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see 326030 company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩573.98 Billion ≈ $388.98 Million	₩94.90 Billion ≈ $64.31 Million	0.165x	+156.33%
2023-12-31	₩320.95 Billion ≈ $217.50 Million	₩-94.20 Billion ≈ $-63.84 Million	-0.294x	+41.90%
2022-12-31	₩316.56 Billion ≈ $214.53 Million	₩-159.92 Billion ≈ $-108.38 Million	-0.505x	-141.62%
2021-12-31	₩444.19 Billion ≈ $301.02 Million	₩-92.87 Billion ≈ $-62.94 Million	-0.209x	+62.39%
2020-12-31	₩379.07 Billion ≈ $256.89 Million	₩-210.73 Billion ≈ $-142.81 Million	-0.556x	-108.90%
2019-12-31	₩-13.03 Billion ≈ $-8.83 Million	₩-81.33 Billion ≈ $-55.12 Million	6.244x	+359.13%
2018-12-31	₩58.63 Billion ≈ $39.73 Million	₩-141.28 Billion ≈ $-95.74 Million	-2.410x	-15.76%
2017-12-31	₩47.24 Billion ≈ $32.02 Million	₩-98.34 Billion ≈ $-66.65 Million	-2.082x	-528.17%
2016-12-31	₩147.69 Billion ≈ $100.09 Million	₩-48.94 Billion ≈ $-33.17 Million	-0.331x	--

About Sk Biopharmaceuticals Co Ltd

KO:326030 Korea Biotechnology

Market Cap

$5.27 Billion

₩7.78 Trillion KRW

Market Cap Rank

#3464 Global

#88 in Korea

Share Price

₩99300.00

Change (1 day)

-0.60%

52-Week Range

₩88500.00 - ₩140700.00

All Time High

₩217000.00